RARE DISEASES A–Z · LETTER N

Neurofibromatosis Type 1

Neurofibromatosis type 1 (NF1) is one of the most common genetic conditions — more frequent than cystic fibrosis and Duchenne dystrophy combined. A faulty tumour-suppressor gene (NF1, making neurofibromin) allows benign tumours to grow on nerves throughout the body, alongside characteristic skin marks and a range of other effects.

By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026

Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.

In short: Neurofibromatosis type 1 is a common genetic tumour-predisposition condition: café-au-lait spots, skin neurofibromas, learning difficulties, and a small risk of deeper tumours. Surveillance, blood pressure control, and a pathway-blocking medicine for plexiform tumours are the care pillars.

The guide

The basics

Neurofibromin is a tumour suppressor — a brake on cell growth signals. With one faulty copy from birth and a second hit acquired in individual cells, Schwann cells (which wrap nerves) overgrow into neurofibromas. The visible signature is café-au-lait spots — flat, coffee-coloured birthmarks, six or more of which are a diagnostic criterion — plus freckling in the armpits and groin, and harmless coloured spots in the iris (Lisch nodules). Neurofibromas grow on or under the skin, sometimes in large numbers from puberty; a deeper type, plexiform neurofibromas, grows along nerve networks and can be disfiguring and painful. Bones can be affected (spine curvature, shin bone bowing), learning difficulties are common in children, and blood pressure can rise from kidney artery narrowing or a rare adrenal tumour. Severity varies enormously — even within one family.

How it works

Diagnosis is clinical using established criteria — combinations of café-au-lait spots, neurofibromas, skinfold freckling, Lisch nodules, optic pathway tumours, characteristic bone changes, and an affected parent — updated to include genetic testing, which finds the NF1 variant in the great majority and can confirm the diagnosis in young children before features fully declare. About half of cases are new mutations, with no family history. Assessment includes skin and neurological examination, eye review (optic pathway gliomas occur in a minority of children), spine and limb checks, developmental and educational assessment, and blood pressure measurement — hypertension in NF1 always deserves a cause hunt. MRI is used for symptomatic or plexiform tumours rather than as blanket screening.

Day to day

There is no cure, but much can be done. Ordinary cutaneous neurofibromas are removed surgically or by laser only when troublesome — they are benign. For inoperable plexiform neurofibromas that cause problems, a MEK inhibitor medicine (which blocks the overactive growth pathway) can shrink tumours and relieve pain, first approved for children and now used more widely; surgery remains an option where anatomy allows. Learning support at school, treatment of ADHD where present, orthopaedic care for scoliosis and shin bowing, and blood pressure treatment follow standard practice. Optic pathway gliomas are usually observed, with chemotherapy if vision is threatened. Psychological support matters: visible difference and chronic uncertainty are real burdens, and NF charities provide strong peer networks.

When to get help

Annual review — in childhood at an NF clinic — tracks growth, development, spine, blood pressure, skin changes, and school progress. Parents learn the plexiform warning signs: a lump that grows quickly, becomes painful without injury, hardens, or causes new weakness or numbness needs prompt assessment because of the small transformation risk. New headaches, visual change, or early puberty in a child should be reported, as they can signal an optic pathway tumour. Adults need continued blood pressure checks and breast screening awareness (risk is modestly raised at younger ages). Genetic counselling clarifies the 1-in-2 inheritance and reproductive options, including embryo and prenatal testing.

See a doctor promptly if: A lump in NF1 that grows rapidly, becomes persistently painful, hardens, or causes new weakness or numbness needs prompt assessment — transformation, though uncommon, must be excluded.

Common questions

What does the NF1 gene do?

Neurofibromin is a brake on a growth signal (RAS). Without it, nerve sheath cells grow too readily — which is why NF1 causes tumours, and why a medicine blocking the pathway downstream (a MEK inhibitor) can shrink plexiform neurofibromas.

My child has a few café-au-lait spots — is it NF1?

Usually not. An isolated café-au-lait spot or two is common in the general population, especially in children. NF1 criteria require six or more spots of sufficient size, or a combination with other features or the gene result. A different condition (Legius syndrome) causes spots without the tumours.

Do the tumours turn cancerous?

Most neurofibromas are benign and stay benign. The plexiform type carries a lifetime risk — roughly one in ten — of transforming into a malignant nerve sheath tumour. New rapid growth, persistent pain, or a hardening lump should always be assessed promptly.

What is the life expectancy?

Life expectancy is somewhat reduced, mainly from the minority who develop malignant tumours or vascular complications. With regular surveillance, blood pressure control, and prompt assessment of changing lumps, most people with NF1 live long, full lives.

More in Letter N

Related

This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Tumour surveillance and blood pressure checks are individual; follow your NF team's schedule.